Evidence map›Paper›PMID 36245982›Full record

ArticleJournal of oncology2022

Correlation Study on the Expression of INSR, IRS-1, and PD-L1 in Nonsmall Cell Lung Cancer.

Ma Ting, Yu-E Miao, Feng-Xiu Yu, Guang-Cai Luo, Xin Xu, Li-Xia Xiao, Guo-Qing Zhang, Jin Chang

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ma TingShandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271000 Shandong Province, China.ORCID https://orcid.org/0000-0002-3157-9639
Yu-E MiaoDepartment of Chemotherapy, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.
Feng-Xiu YuBasic Medical College, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, 271000 Shandong Province, China.
Guang-Cai LuoDepartment of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.
Xin XuDepartment of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.
Li-Xia XiaoThe Second Affiliated Hospital of Shandong First Medical University, Tai'an, 271000 Shandong Province, China.
Guo-Qing ZhangDepartment of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.ORCID https://orcid.org/0000-0002-6820-4072
Jin ChangDepartment of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China.ORCID https://orcid.org/0000-0003-3308-1954
Affiliated Hospital of Taishan Medical University · CNShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To study the expression and correlation of insulin receptor (INSR), insulin receptor substrate-1 (IRS-1), and programmed cell death ligand-1 (PD-L1) in nonsmall cell lung cancer (NSCLC). Methods: 45 lung cancer tissues and 30 adjacent normal tissues of NSCLC patients diagnosed in the Second Affiliated Hospital of Shandong First Medical University from June 2019 to August 2020 were selected. The expressions of INSR, IRS-1, and PD-L1 proteins in tumor tissues and adjacent tissues of NSCLC were detected by immunohistochemical staining. Results: The expression of INSR and IRS-1 in NSCLC was significantly higher than that in adjacent normal lung tissue ( Conclusion: IRS-1 may be involved in the regulation of PD-L1 expression and mediate the occurrence of tumor immune escape, which is expected to become a new target for NSCLC immunotherapy and provide new clinical evidence for immunosuppressive therapy.

Identifiers

PMID36245982
PMCPMC9553505
OpenAlexW4301182628

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.